Latest From Spiracur Inc.
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced November-December 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
- Medical Devices
- Therapeutic Areas
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Spiracur Inc.
- Senior Management
Chris Fashek, Pres. & CEO
Steven Van Dick, VP, Fin. & Admin. & CFO
Kenton Fong, MD, CSO
Dane Shackleford, VP, Global Sales & Mktg.
Larry Hu, VP, R&D & Operations
Yousuf Mazhar, VP, Bus. Dev.
- Contact Info
Phone: (408) 701-5300
1180 Bordeaux Dr.
Sunnyvale, CA 94089
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.